HEALTH● LOWJun 26 · Jun 26, 2026, 1:59 PM
Capricor falls as FDA sets up AdCom meeting to review Duchenne therapy
Seeking Alpha Tech
Capricor's stock has decreased in value following the FDA's announcement of an Advisory Committee meeting to review its Duchenne therapy. This signals a key regulatory step for the potential treatment.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH35m agoScientists confirm fruit and vegetable skin really is good for youNew ScientistHEALTH37m agoNipah medicine row: Action after receiving expert panel report, says Keralam Health MinisterThe HinduHEALTH2h ago“Age is not a limit for sex”: the 5 best sexual positions after 60ClarínHEALTH2h agoDoes food addiction exist? The answer will surprise youClarín